Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab

Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection...

Full description

Bibliographic Details
Main Authors:	Menke, Marcel N., Salam, Adzura, Framme, Carsten, Wolf, Sebastian
Format:	Article
Language:	English
Published:	S. Karger AG 2013
Subjects:	RE Ophthalmology
Online Access:	http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/3/adzura.pdf

id	iium-31705
recordtype	eprints
spelling	iium-317052019-08-05T01:52:34Z http://irep.iium.edu.my/31705/ Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab Menke, Marcel N. Salam, Adzura Framme, Carsten Wolf, Sebastian RE Ophthalmology Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright © 2013 S. Karger AG, Basel. S. Karger AG 2013-04 Article PeerReviewed application/pdf en http://irep.iium.edu.my/31705/3/adzura.pdf Menke, Marcel N. and Salam, Adzura and Framme, Carsten and Wolf, Sebastian (2013) Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab. Ophthalmologica, 229 (3). pp. 168-172. ISSN 0030-3755 http://dx.doi.org/10.1159/000346397 10.1159/000346397
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	RE Ophthalmology
spellingShingle	RE Ophthalmology Menke, Marcel N. Salam, Adzura Framme, Carsten Wolf, Sebastian Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
description	Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright © 2013 S. Karger AG, Basel.
format	Article
author	Menke, Marcel N. Salam, Adzura Framme, Carsten Wolf, Sebastian
author_facet	Menke, Marcel N. Salam, Adzura Framme, Carsten Wolf, Sebastian
author_sort	Menke, Marcel N.
title	Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_short	Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_full	Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_fullStr	Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_full_unstemmed	Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab
title_sort	long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab
publisher	S. Karger AG
publishDate	2013
url	http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/ http://irep.iium.edu.my/31705/3/adzura.pdf
first_indexed	2023-09-18T20:45:51Z
last_indexed	2023-09-18T20:45:51Z
_version_	1777409669991497728

Long-Term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with Ranibizumab

Similar Items